EATG will have a webinar for community members about the EHVA T02 trial. EHVA T02 is a Phase II trial that will evaluate an experimental therapeutic HIV vaccine and an immunotherapy drug for people living with HIV. The trial is taking place in France, Switzerland, and the UK and will evaluate the safety and tolerability of the experimental vaccine with the antibody, or the antibody alone. Further, this trial will see if either regiment can control HIV infection following interruption of antiretroviral therapy.
The Webinar will take place on Zoom, on Wednesday, 13 July 2022 at 16:00 – 17:30 CET.
Link for registration
The webinar is open to anyone interested. To attend the e-meeting, please register here.
Agenda
| Welcome & Introduction | Giulio Maria Corbelli – EATG |
| The EHVAT02 trial design and implications for MVA vaccination related to monkeypox infection | Jean-Daniel Lelievre – CHU Henri Mondor |
| The social science sub-study | Christel Protiere – SESSTIM (AMU – Inserm – IRD) |
| Informed consent process and enrolment procedures and key elements for potential participants | Sheena Mc Cormack – MRC CTU at University College London |
| Discussion | Moderator: Giulio Maria Corbelli – EATG |
| Conclusion & Follow Up | Giulio Maria Corbelli – EATG |
The European HIV Alliance (EHVA) is a five year project funded by the European Union’s Horizon 2020 Research and Innovation Programme designed to foster the development of an effective vaccine. More information at www.ehv-a.eu.
Practical Information
- Webinar on the EHVA T02 trial for a Therapeutic Vaccine: Zoom Webinar: 13 July 2022 at 16:00 – 17:30 CET
Co-organisers:
European AIDS Treatment Group
EHVA
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.